All In Biotech

Drug Trial Radar · NCT07336446

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Jan 27, 2026

Primary completion

Nov 5, 2026

Study completion Nov 5, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

Conditions

  • Prostate Cancer

Interventions

  • AZD9750Drug

    AR-PROTAC

  • AZD5305Drug

    PARP1-selective inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first dose of study intervention to 28 days post first dose
  2. Number of participants with Adverse Events and Serious Adverse EventsTime frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  3. Number of participants with Adverse Events leading to discontinuation of study interventionTime frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  4. Clinically significant changes from baseline in vital signs.Time frame: From first study dose up to 37 days after the last dose of study treatment
  5. Clinically significant changes from baseline in physical examination.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  6. Clinically significant changes from baseline in ECOG PS.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  7. Clinically significant changes from baseline in ECGs.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  8. Clinically significant changes from baseline in laboratory parameters.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
  9. Proportion of participants achieving a ≥50% decrease in PSA from baseline (PSA50) (Part B only)Time frame: From first dose of study intervention up to 14 days after the last dose of study treatment

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Nashville, Tennessee

  • Research Site

    Melbourne, Australia

  • Research Site

    Kashiwa, Japan

  • Research Site

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.